Lemtrada Can Cause Sudden Death And Many Other Health Issues

Lemtrada Stroke Lawsuit News

Here is a complete list of Lemtrada's short and long-term side effects

Monday, March 8, 2021 - Lemtrada (alemtuzumab) is a dangerous chemotherapy drug used to treat only the most advanced cases of relapse remitting multiple sclerosis (RRMS). Late-stage RRMS is described as, "The most common symptoms include fatigue, walking difficulties, bowel and bladder disturbances, vision problems, changes in brain function, changes in sexual function, pain and depression or mood swings," according to an article in Canadian Virtual Hospice. Patients that are approved for the 5-day treatment must have tried at least two other advanced disease-modifying therapies before attempting Lemtrada. Lemtrada may only be administered in a hospital with a functioning and fully-staffed emergency room, and only after the doctor and patient complete and sign a lengthy risk/reward assessment questionnaire. Most Lemtrada patients elect to stay in the hospital for the duration of the 5 days for convenience, and also to be monitored for the signs of ischemia that could lead to a stroke or a heart attack. After five days, the patient must return every month for a series of blood chemistry tests. Despite the risks and inconveniences, many RRMS patients report that the drug slowed the progression of the disease, and/or, lengthened the duration of the remission periods. Lemtrada Stroke lawsuits continue to be filed by American's in the United States due to long-term effects and national attorneys representing "we the people" are offering a free consultation before filing a claim.

Unfortunately, Lemtrada has side effects that go beyond the initial stroke and heart attacks. According to Multiple Sclerosis Trust in the UK, "Lemtrada works by binding to and killing T-cells (lymphocytes). 1 in 5 people develop an autoimmune disease after treatment; as their immune system grows back, it begins to attack other parts of their body, most commonly the thyroid gland." There are also a host of other side effects that come with taking Lemtrada according to the website, such as, mild to moderate and short-lived headaches, rashes, fever, and nausea, and patients can be given drugs to minimize the discomfort. Other more serious side effects include infusion-related infections, coughs, colds, chest infections, and herpes virus infections (such as cold sores or shingles), according to MST. Patients are often given antibiotics to minimize the risks of infection and antiviral drugs to prevent herpes for up to one month before beginning Lemtrada. The thyroid gland, blood clotting problems, and kidney problems may occur in more than 1% of Lemtrada patients.

A Lemtrada patient should be in good physical condition before Lemtrada is undertaken. Prospective Lemtrada patients need to have blood and urine tests for more than one month to check on their thyroid and kidney functions. Vaccinations should not be taken for more than six months before starting Lemtrada.

In May of 2014, the 13th Lemtrada stoke victim was reported to The US Food and Drug Administration (FDA), setting off the current health concern. It was not until November of 2018 that the FDA came out with a formal health advisory alerting physicians to think twice before prescribing the drug. The FDA announcement read, "The U.S. Food and Drug Administration (FDA) is warning that rare, but serious, cases of stroke and tears in the lining of arteries in the head and neck have occurred in patients with multiple sclerosis (MS) shortly after they received Lemtrada (alemtuzumab).

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.